🩺 Health Futures #32

Happy Monday 👋

This week in health, the pharmaceutical sector saw the Biden Administration set prices for the first ten drugs under the Inflation Reduction Act. In biotechnology, Nuntius Therapeutics and Taiho Pharmaceutical are advancing mRNA-based cancer treatments through a new partnership. Australia is facing a nationwide IV fluid shortage, impacting surgeries and drug administration, with supplies expected to stabilize by the end of the year. On the funding front, Caresyntax secured $180M in Series C funding to expand its precision surgery platform.

💉 Pharmaceuticals

 💊 Novo Nordisk Pharmatech expanded production capacity. Novo Nordisk Pharmatech invested $200M to build a new production facility to meet increased demand for raw materials after acquiring a site in Køge, Denmark, in March. The facility is expected to commence operations in 2027.

🏥 Biden Administration sets prices for first ten drugs. The Biden administration released the government-set prices for the first ten medicines selected under the Inflation Reduction Act (IRA).

🩺 Aurobindo Pharma to commercialize major pharmaceutical plants in India. Aurobindo Pharma, an Indian pharmaceutical company, plans to commercialize its large Pen-G pharmaceutical plant in Andhra Pradesh, India. Aurobindo planned to start a small volume rollout in the November-December period and expects to ramp it up in January-March next year.

🧬 BioTech

🔬 Nuntius partners with Taiho to develop mRNA cancer therapies. Nuntius Therapeutics partnered with Taiho Pharmaceutical to develop next-generation mRNA cancer immunotherapies.

🏛️ Lawmakers raised concerns over China's military-linked clinical trials. House lawmakers are urging the FDA to investigate clinical trials conducted in collaboration with China's military as they prepare to vote on the Biosecure Act, which aimed to address concerns about China's biopharmaceutical industry.

🧪 Sychron, BrainGate, and Clinatec ahead of Neuralink in clinical trials for BCI. Neuralink implanted its device telepathy to two paralysed patients, which the other tech companies are further across the clinical trial process under the FDA Sychron implanted its device to six patients concurrently Walgreens partners with BARDA to innovate in the area of decentralized clinical trials.

🚚 Health Supply Chain

🍼 Northumbria Healthcare NHS Foundation Trust launched an e-prescription system. Northumbria Healthcare NHS Foundation Trust announced it implemented its life with an EPS from CLEO Systems in its pregnancy assessment unit. 

💉 Australia's IV fluids shortage impacted surgeries nationwide. Australia is experiencing a shortage of sterile intravenous (IV) fluids, which is a critical issue for doctors performing surgeries across the country. The supplies of two of the most common solutions are critically low.

🔊 Sound Pharmaceuticals to continue its partnership with WuXi for drug marketing. Sound Pharmaceuticals maintained its relationship with WuXi AppTec for marketing its flagship drug SPI-1005 despite potential concerns related to the Biosecure Act. SP1-1005 is a drug that helps protect the ear cells and reduce inflammation.

💰 Deals of the Week

🩺 Caresyntax, a company providing a vendor-neutral precision surgery platform, secured $180M in Series C funding. The company aims to use the funds to expand operations and its development efforts.

🧫 Pathalys Pharma, a company that develops treatments for kidney disease, raised $105M in Series B funding. The company will use the funds to finalize the two ongoing Upacicalcet clinical trials.

🧪 XII Medical, a clinical-stage medical technology company in California, raised $45M in Series B financing. The company intends to use the funds to further product and clinical development.

🧬 Vandria, a mitochondrial therapeutics company, raised an undisclosed amount in its second Series A funding, bringing the total amount to $30.7M. The funds are expected to expand operations and accelerate its development efforts.

📦 Clarium, which supports hospital supply chain operations, raised $10M in funding. The company plans to use the funds to recruit talent across data science, engineering, sales, product, and customer success teams.

Thank you for reading. Have a great week ahead!
Have some feedback or suggestions? Let us know at hello@holoniq.com